Find a study
Browse recruiting studies near you — free to check, always your choice.
19 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Heart / cardiovascular diseaseKidney disease💵 May compensate
📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.
- Obesity / overweightHeart / cardiovascular disease💵 May compensate
📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).
- COPD (chronic lung disease)💵 May compensate
📍 University of Alabama at Birmingham · Birmingham, AL · +4 more US sites · Get directions →
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ.
- Multiple sclerosis (MS)
📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
- Lupus (SLE)💵 May compensate
📍 Alloy Clinical Research LLC · Kissimmee, FL · +10 more US sites · Get directions →
The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod.
- Obesity / overweightHigh blood pressure💵 May compensate
📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.
- Obesity / overweightHeart / cardiovascular disease💵 May compensate
📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.
- Obesity / overweightHeart / cardiovascular disease💵 May compensate
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: \- Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see the amount of blood vessel narrowing and vessel wall thickness.
- Heart / cardiovascular diseaseKidney disease
📍 University of Michigan · Ann Arbor, MI · Get directions →
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system but also the renal, neuroendocrine, and immune systems.
- COPD (chronic lung disease)
📍 University of Tennessee Medical Center · Knoxville, TN · Get directions →
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
- COPD (chronic lung disease)💵 May compensate
📍 John D. Dingell VA Medical Center, Detroit, MI · Detroit, MI · Get directions →
Cognitive dysfunction in the aging Veteran population is a growing health concern in the Veterans Health System. It is not known whether OSA coexisting with COPD will enhance the risk for cognitive dysfunction.
- COPD (chronic lung disease)💵 May compensate
📍 Beth Israel Deaconess Medical Center · Boston, MA · Get directions →
The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the potential role of lung fissure completion with pleural adhesiolysis strategy (experimental intervention) in severe emphysema/COPD patients with failed bronchoscopic lung volume reduction (BLVR) via the use of endobronchial valves (EBVs) therapy. In select patients, the lung fissure completion with adhesiolysis strategy will be performed by video-assisted thoracoscopic surgery (VATS) guided stapling along the lung fissures to reduce collateral ventilation with adhesions removal and determine whether this experimental strategy will improve outcomes after failed BLVR in patients with severe emphysema/COPD.
- Multiple sclerosis (MS)
📍 Washington University in St. Louis · St Louis, MO · Get directions →
This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, \[18F\]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.
- COPD (chronic lung disease)💵 May compensate
📍 Research Site · Buenos Aires, · Get directions →
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Lupus (SLE)💵 May compensate
📍 Research Site · Buenos Aires, · Get directions →
INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations.
- COPD (chronic lung disease)💵 May compensate
📍 Univeristy of Alberta & Alberta Health Services · Edmonton, Alberta · Get directions →
Lung transplantation is a complex procedure performed in patients with terminal lung disease. The transplant procedure stresses the patient's heart and lungs, which are already taxed by the underlying disease process.
- High blood pressure💵 May compensate
📍 Hospital Paitilla Clinicas y Hospitales · Panama City, · Get directions →
This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.
- Heart / cardiovascular disease💵 May compensate
📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.
- COPD (chronic lung disease)
📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →
This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.